Mercer Global Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.1M | Buy |
1,165,477
+230,253
| +25% | +$6.02M | 0.03% | 282 |
|
|
2026
Q1 | $26.3M | Buy |
935,224
+126,172
| +16% | +$3.36M | 0.04% | 264 |
|
|
2025
Q4 | $20.1M | Buy |
809,052
+47,067
| +6% | +$1.19M | 0.03% | 333 |
|
|
2025
Q3 | $19.4M | Sell |
761,985
-19,243
| -2% | -$475K | 0.03% | 319 |
|
|
2025
Q2 | $18.9M | Sell |
781,228
-64,121
| -8% | -$1.5M | 0.04% | 256 |
|
|
2025
Q1 | $21.4M | Buy |
845,349
+105,169
| +14% | +$2.75M | 0.05% | 214 |
|
|
2024
Q4 | $19.6M | Sell |
740,180
-189,942
| -20% | -$5.15M | 0.05% | 217 |
|
|
2024
Q3 | $26.7M | Buy |
930,122
+33,105
| +4% | +$966K | 0.06% | 163 |
|
|
2024
Q2 | $17.6M | Buy |
897,017
+5,246
| +0.6% | +$144K | 0.05% | 206 |
|
|
2024
Q1 | $24.8M | Sell |
891,771
-93,752
| -10% | -$2.6M | 0.07% | 168 |
|
|
2023
Q4 | $28.4M | Sell |
985,523
-76,414
| -7% | -$2.31M | 0.09% | 155 |
|
|
2023
Q3 | $35.2M | Sell |
1,061,937
-33,042
| -3% | -$1.17M | 0.13% | 106 |
|
|
2023
Q2 | $40.2M | Buy |
1,094,979
+82,217
| +8% | +$3.2M | 0.16% | 96 |
|
|
2023
Q1 | $41.3M | Buy |
1,012,762
+7,796
| +0.8% | +$337K | 0.19% | 84 |
|
|
2022
Q4 | $51.5M | Buy |
1,004,966
+70,920
| +8% | +$3.4M | 0.26% | 64 |
|
|
2022
Q3 | $40.9M | Buy |
934,046
+48,444
| +5% | +$2.35M | 0.24% | 69 |
|
|
2022
Q2 | $46.4M | Buy |
885,602
+82,900
| +10% | +$4.22M | 0.28% | 61 |
|
|
2022
Q1 | $41.6M | Buy |
802,702
+55,816
| +7% | +$2.9M | 0.24% | 65 |
|
|
2021
Q4 | $44.1M | Buy |
746,886
+103,188
| +16% | +$5.11M | 0.27% | 60 |
|
|
2021
Q3 | $27.7M | Buy |
643,698
+42,015
| +7% | +$1.86M | 0.19% | 82 |
|
|
2021
Q2 | $23.6M | Buy |
601,683
+31,910
| +6% | +$1.24M | 0.18% | 93 |
|
|
2021
Q1 | $20.6M | Buy |
569,773
+731
| +0.1% | +$26K | 0.19% | 92 |
|
|
2020
Q4 | $20.9M | Sell |
569,042
-8,903
| -2% | -$327K | 0.26% | 63 |
|
|
2020
Q3 | $20.1M | Buy |
577,945
+1,117
| +0.2% | +$39.2K | 0.3% | 57 |
|
|
2020
Q2 | $17.9M | Buy |
576,828
+21,802
| +4% | +$741K | 0.32% | 53 |
|
|
2020
Q1 | $17.2M | Sell |
555,026
-17,871
| -3% | -$609K | 0.38% | 51 |
|
|
2019
Q4 | $21.3M | Buy |
572,897
+103,102
| +22% | +$3.67M | 0.43% | 49 |
|
|
2019
Q3 | $16M | Buy |
469,795
+94,223
| +25% | +$3.43M | 0.38% | 59 |
|
|
2019
Q2 | $15.4M | Buy |
375,572
+56,108
| +18% | +$2.23M | 0.41% | 56 |
|
|
2019
Q1 | $12.9M | Buy |
+319,464
| New | +$12.8M | 0.46% | 47 |
|
Other funds holding PFE
Mercer Global Advisors's PFE Position: Q2 2026 in Review
Mercer Global Advisors increased its Pfizer (PFE) stake by 25% in Q2 2026, buying an estimated $6.02M and bringing the position to 1,165,477 shares worth $28.1M. The position accounts for 0.03% of the portfolio, ranked #282.
Mercer Global Advisors first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $51.5M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Mercer Global Advisors held 1,165,477 shares of Pfizer worth $28.1M as of Q2 2026.
- Mercer Global Advisors bought 230,253 Pfizer shares in Q2 2026, an estimated $6.02M.
- Pfizer made up 0.03% of Mercer Global Advisors's portfolio in Q2 2026, its #282 holding.
- Mercer Global Advisors first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
- Mercer Global Advisors's Pfizer position peaked at $51.5M in Q4 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.